3-n-Butylphthalide (NBP)

Chinese-approved multi-target neuroprotectant derived from celery seed; A-tier evidence in China for acute ischemic stroke (BAST 2023, n=1,216, OR 1.70 for favorable mRS) and B-tier for post-stroke cognitive impairment + mild cognitive impairment (EBMCI 2024, n=270, ADAS-cog −2.04 vs placebo). For Dylan: OPTIONAL-WITH-CAVEATS / LOW confidence — mechanism overlaps cleanly with cerebrolysin's neuroprotection thesis (oral, cheaper, ~$30-80/mo) but the entire evidence base is Chinese stroke/dementia populations, not MMA subconcussive prophylaxis. Hepatotoxicity signal (1.4-17.5% ALT elevation) is the main watch item; mitigated by NAC already in V4.

NBP is a small phthalide (C₁₂H₁₄O₂, MW 190.2) originally isolated from the seeds of celery (Apium graveolens). The clinically used product is the racemic DL form (CAS 6066-49-5); the natural L-enantiomer (CAS 3413-15-8) is also pharmacologically active and used in some preparations. It crosses the BBB (lipophilic small molecule, no transporter dependency) and accumulates in brain tissue.

The defining feature is mechanism breadth, not single-target potency — much like cerebrolysin, NBP hits multiple convergent neuroprotection pathways at once, which is why it shows clinical effect across ischemic, hemorrhagic, traumatic, and small-vessel-disease pathologies but is not a felt nootropic.

Layer 1 — Microcirculation and platelet:

• Reduces platelet aggregation (anti-thromboxane A2, anti-cyclic AMP-mediated platelet activation)
• Increases cerebral blood flow in ischemic regions; promotes collateral circulation
• Reduces post-ischemic cerebral edema and tightens BBB

Layer 2 — Mitochondrial protection (the most-studied 2024-2025 mechanism):

• AMPK / PGC-1α activation → upregulates mitochondrial biogenesis genes (NRF1, TFAM); restores ATP production after ischemia/reperfusion (2025 ScienceDirect)
• Mfn1-mediated mitochondrial fusion → preserves mitochondrial network integrity (Frontiers in Pharmacology 2024)
• mPTP (mitochondrial permeability transition pore) closure → prevents apoptotic cytochrome c release; preserves membrane potential (ΔΨm); reduces ROS generation
• GCN5L1-mediated Drp1 acetylation suppression → reduces pathological mitochondrial fission (CNS Neurosci Ther 2025)
• Sirt1/Nrf2 axis activation in I/R-injured tissue (PubMed 39614673, 2024)

Layer 3 — Antioxidant (Nrf2/Keap1 pathway):

• Activates Nrf2 → upregulates endogenous antioxidant gene battery: SOD, GPx, catalase, HO-1, NQO1
• Reduces malondialdehyde (MDA), restores SOD/GPx activity in TBI and ischemic models
• Lipid peroxidation suppression → membrane integrity preservation

Layer 4 — Anti-neuroinflammatory:

• Suppresses NF-κB activation → reduces TNF-α, IL-1β, IL-6
• Inhibits microglial M1 polarization (TLR4/MyD88 axis)
• Anti-ferroptotic via AHR-CYP1B1 pathway (2024 TBI rodent data, J Ethnopharmacol)
• Reduces astrocyte reactivity (GFAP)

Layer 5 — Anti-apoptotic and pro-regenerative:

• Bcl-2 ↑, Bax ↓, caspase-3 ↓ (canonical anti-apoptotic axis — same downstream as cerebrolysin and SS-31)
• Wnt/β-catenin pathway activation → promotes adult neurogenesis (subgranular zone, subventricular zone) (Mol Neurobiol 2025)
• Upregulates BDNF, VEGF, eNOS, MMP-9 in TBI models — angiogenesis + arteriogenesis + neurogenesis
• Reduces tau hyperphosphorylation; suppresses BACE1 (Alzheimer's-relevant mechanism)
• Akt/mTOR signaling activation (anti-autophagy in pathological states)

Plain English: NBP tells brain cells in low-oxygen / impact-stressed states to keep their mitochondria functioning, dampens the inflammatory cascade that turns acute injury into chronic damage, and supports the regrowth machinery (BDNF, neurogenesis, angiogenesis) downstream. It is not a stimulant or felt nootropic. The on-cycle subjective signal in healthy users is subtle to absent — this is true insurance / disease-modifying logic, not a Tuesday-afternoon-different drug.